arrow
M

Marta Doménech

institut investigació germans trias i pujol
H指数:15
被引数:810

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer

ARIAN方案:一项关于Sacituzumab和Zimberelimab治疗非小细胞肺癌患者的III期研究

2026-05-250
PRE
Implementing a Molecular Prescreening Strategy for Tumors Without Public NGS Access in a Cancer Center Network: Results from the PREICO Project

在无公共NGS访问权限的肿瘤中心网络中实施分子预筛选策略:PREICO项目的结果

2026-04-040
PRE
Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study

真实世界下一代测序揭示的神经胶质瘤的临床可操作性: 一项多中心研究

2026-01-060
OAAI
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

诱导avelumab,然后进行化学免疫疗法和维持与单独化疗作为顺式不合格转移性尿路上皮癌的一线治疗 (INDUCOMAIN): 一项随机II期研究

2024-09-010
OAAI
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

用免疫疗法治疗的具有KRAS突变的转移性肺癌患者队列的特征: 根据KRAS G12C与non-G12C的差异

2023-10-174
OAAI
In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma
2022-08-243
OAAI
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG ANITA
2021-07-0112
OAAI
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
2020-04-2465
OAAI
EXTENDING ADJUVANT TEMOZOLOMIDE LONGER THAN SIX CYCLES DOESN'T ADD ANY BENEFIT TO GLIOBLASTOMA PATIENTS ACCORDING TO THE RANDOMIZED GEINO-014 TRIAL
2019-09-060
OAAI
PREVALENCE AND CHARACTERISTICS OF NOCTURNAL HYPERTENSION IN PREHYPERTENSIVE SUBJECTS
2015-06-010
OAAI